A Double Blind (3rd Party Open), Randomised, Placebo Controlled, Dose Escalation Study To Investigate The Safety, Toleration, And Pharmacokinetics Of Multiple Inhaled Doses Of PF-03526299 In Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2010
At a glance
- Drugs PF 3526299 (Primary)
- Indications Asthma
- Focus Adverse reactions
- 23 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Dec 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 17 Dec 2009 Additional location (Singapore) identified as reported by ClinicalTrials.gov.